Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,859 1,952 1,974 1,888 1,592 1,360   5,127
Vimpat 1,451 1,541 974 627 525 468 418   1,939
Keppra  788 846 703 615 555 510 467   2,153
Briviact 288 353 428 494 556 606 578 624 1,730
Neupro 311 304 274 244 214 194 177   689
New Products
(global sales, non-risk adj.)
                 
Evenity    472 654 804 936 1,047 1,129 1,354 2,169
Nayzilam 26  48 74 98 119 136 137 162 368
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimzelx    25 215 547 960 1,365 1,757 2,991 6,349
Zilucoplan   0 6 104 244 392 543 1,022 1,973
Rozanolixizumab    0 5 71 179 325 468 934 1,419
Dapimab   0 0 0 3 44 148    
Staccato alprazolam   0 0 2 25 72 114 286   
Bepranemab   0 0 0 17 56 90    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052   5,332  5,041  5,141 5,559  5,839
Revenue 5,347   5,634 5,307  5,397  5,812  6,087 
Adjusted EBIT 1,093   1,248 1,069  1,142 1,413   1,611
Adjusted EBITDA 1,441   1,591 1,416  1,528  1,818  2,019 
Net Profit*  732  986  814  879  1,116  1,290 
Core EPS (€) 5.36  5.99 5.12 5.55 6.85  7.78 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,856 1,969 2,005 1,874 1,570 1,299   4,803
Vimpat 1,451 1,540 973 626 536 485 435   1,845
Keppra  788 863 718 634 573 519 481   1,880
Briviact 288 350 426 496 555 610 583 640 1,664
Neupro 311 306 276 250 211 191 172   555
New Products
(global sales, non-risk adj.)
                 
Evenity    478 631 768 893 991 1,037 1,375 2,148
Nayzilam 26  48 73 96 118 130 134 161 373
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimzelx   17 220 604 951 1,313 1,723 2,614 5,682
Zilucoplan   0 0 89 249 386 552 1,016 1,912
Rozanolixizumab    0 0 79 169 333 461 1,020 1,378
Dapimab   0 0 0 0 50 140    
Staccato alprazolam   0 0 0 22 59 83 253   
Bepranemab   0 0 0 0 20 27    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052  5,353  4,994  5,154 5,590   5,936
Revenue 5,347  5,633  5,264   5,423 5,847  6,187 
Adjusted EBIT 1,093  1,236  1,052  1,188  1,457 1,592 
Adjusted EBITDA 1,441  1,578 1,371  1,558  1,864   2,011
Net Profit*  732  990  814  900  1,127 1,293
Core EPS (€) 5.36  6.03 5.07  5.71  6.91  7.68 

*attributable to UCB shareholders

Downloads:
UCB FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 27 January 2022



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.